To Content Pane
Important Notice: The CUTV website has been migrated. We sincerely invite you to visit our YouTube channel @CUHKchannel for more engaging videos.
Close banner

"CUHK Innovations that Changed the World" - Professor Tony Mok Precision Medicine for Management of Lung Cancer

17 Dec, 2021
Professor Tony Shu Kam MOK, Chairman of the Department of Clinical Oncology and Li Shu Fan Medical Foundation Professor of Clinical Oncology of CU Medicine, published the IRESSA Pan-Asia Study (IPASS), which is a landmark study that established for the first-time targeted therapy as the first-line treatment in adenocarcinoma patients harbouring epidermal growth factor receptor (EGFR) mutation in 2009. It proved that targeted therapy in non-smoking Asian adenocarcinoma patients has a higher efficacy than the conventional intravenous chemotherapy. Furthermore, in 2014, Professor Mok published another study proving that molecular targeted therapy is superior to standard first-line chemotherapy in ALK-positive lung cancer patients. Now selective patients with driver oncogenes may survive beyond 3 to 5 years.
The major breakthroughs in the clinical studies led by Professor Mok have defined a new treatment paradigm for mutated lung cancer. Currently, doctors will check for EGFR or ALK mutation before prescribing a customised treatment plan. For patients with EGFR mutation or who are ALK-positive, targeted therapy will be the standard first-line treatment. This puts personalised medicine into practice which helps cancer patients live better and for longer.
Watch the video and learn more about his research!

Categories / Series:


Share to: